Weekly Digest – March 2025 Weekly Digest – March 2025 21 Mar 2025: Eisai’s abandoned Enhertu challenger set to live on at BlissBio Eisai decided not to exercise its option to acquire BB-1701, a HER2-directed antibody-drug conjugate (ADC) from Bliss […]
Weekly Digest – March 2025 Weekly Digest – March 2025 26 Mar 2025: GV20 Therapeutics announces collaboration agreement with Mitsubishi Tanabe Pharma Corporation to develop novel antibody-drug conjugates GV20 Therapeutics and Mitsubishi Tanabe Pharma Corporation (MTPC) have entered a strategic […]
Weekly Digest – March 2025 Weekly Digest – March 2025 18 Mar 2025: JSKN003 was granted Breakthrough Therapy Designation in China JSKN003, a HER2-targeting ADC, has been granted BTD by China’s National Medical Products Administration (NMPA) for the treatment of […]
Weekly Digest – March 2025 Weekly Digest – March 2025 19 Mar 2025: DATROWAY launched in Japan as the first TROP2 directed therapy for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer DATROWAY (datopotamab deruxtecan) […]
Weekly Digest – March 2025 Weekly Digest – March 2025 19 Mar 2025: AstraZeneca offers early look at Datroway-Tagrisso combo in EGFR lung cancer as phase 3 trial rolls on AstraZeneca has released early data from a Phase 2 trial […]
Weekly Digest – March 2025 Weekly Digest – March 2025 20 Mar 2025: Elevation Oncology to discontinue development of EO-3021, advancing EO-1022 while evaluating strategic options Elevation Oncology will discontinue development of EO-3021, a Claudin 18.2 ADC, after Phase 1 […]
Weekly Digest – March 2025 Weekly Digest – March 2025 17 Mar 2025: Taiho Pharmaceutical to acquire next-generation ADC drug discovery company Araris Biotech Taiho Pharmaceutical has entered into a definitive agreement to fully acquire Araris Biotech, a swiss biotechnology […]
Weekly Digest – March 2025 Weekly Digest – March 2025 19 Mar 2025: Oxford BioTherapeutics enters into a strategic collaboration with Roche to discover novel targets for antibody-based therapeutics for the treatment of cancer Oxford BioTherapeutics (OBT) has partnered with […]
Weekly Digest – March 2025 Weekly Digest – March 2025 10 Mar 2025: Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) approved for marketing in second indication by NMPA for EGFRm NSCLC • Sichuan Kelun-Biotech’s TROP2-directed ADC, sac-TMT, is now approved in […]
Weekly Digest – March 2025 Weekly Digest – March 2025 12 Mar 2025: Zai Lab announces acceptance of biologics license application for TIVDAK for the treatment of patients with recurrent or metastatic Cervical cancer Zai Lab announced that China’s NMPA […]
